USANA Exec. Chairman Kevin Guest Celebrates Guitar Month, Stress Awareness Month for Harmony
While music has long been heralded as a universal remedy, the guitar offers far more than just melodies. Studies, stories and specialists alike agree: playing the guitar is a proven method to reduce stress.
A passionate, performing guitarist himself, Guest invites others to join the cause. "Music has the extraordinary ability to uplift and inspire, and I encourage everyone to immerse themselves in the joy of playing guitar this month. It's a simple, powerful way to enhance your well-being."
Because playing guitar nurtures both mind and soul, Guest reveals six ways it boosts mental well-being.
Stress Escape: Anyone can lose themselves in music and find calm in the strums.
Boosted Mood: Playing guitar releases dopamine, the happiness chemical.
Mindfulness: Focusing on music reduces anxiety and centers one's mind.
Social Connection: Sharing music builds powerful, emotional bonds.
Creative Outlet: Songwriting expresses emotions and eases stress.
Better Sleep: Relaxing guitar sessions lead to improved rest.
In his bestselling book, "All the Right Reasons: 12 Timeless Principles for Living a Life in Harmony," Guest emphasizes how music minimizes stress and strengthens relationships that matter, "When I was young, I lived music down to my bones, and harmonies played constantly in my head. I wanted to be a rock star more than anything else.
"Today, music speaks to the soul like nothing else can. This love for music, this awe I have for the process, has been with for me as long as I can remember. Music has transformed my life and offered calmness and clarity where there was chaos. When anxiety takes hold, a melody actually soothes my nerves. Whether it's a soft tune or a lively rhythm with bands I play in, music brings a peace I never thought possible. It's been my strength, saving me more times than I can count."
More inspiring examples of the power of the power of music are shared throughout All the Right Reasons, where all proceeds go to feeding hungry children. Each book purchase provides 40 meals. For more information, visit www.kevinguest.com.
USANA Health Sciences (NYSE: USNA), a global leader in health and wellness products, has long recognized the importance of social wellness in building a successful business. From its founding in 1992, USANA has focused on clear and concise communication to build trust with its customers and distributors in 25 countries. For more information about USANA Health Sciences and its dedication to promoting health, wellness, and entrepreneurial success, visit USANA.com.
MEDIA CONTACT: Tim Brown, Candid Communications tim@candidcom.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/usana-exec-chairman-kevin-guest-celebrates-guitar-month-stress-awareness-month-for-harmony-302416134.html
SOURCE USANA
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2025/01/c3583.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
a day ago
- Business Wire
Alibaba Group Prices Offering of HK$12.023 Billion of Zero Coupon Exchangeable Bonds
HONG KONG--(BUSINESS WIRE)--Alibaba Group Holding Limited (NYSE: BABA and HKEX: 9988 (HKD Counter) and 89988 (RMB Counter), 'Alibaba,' 'Alibaba Group' or the 'Company') today announced the pricing of its private offering (the 'Bond Offering') of HK$12.023 billion aggregate principal amount of Zero Coupon Exchangeable Bonds due 2032 (the 'Bonds') by reference to the ordinary shares of Alibaba Health Information Technology Limited ('Alibaba Health') that are listed on The Stock Exchange of Hong Kong Limited (the 'Hong Kong Stock Exchange') (HKEX: 00241) ('AH Shares'). The Bonds were offered to certain non-U.S. persons in offshore transactions outside the United States in reliance on Regulation S under the U.S. Securities Act of 1933, as amended (the 'Securities Act'). The Bond Offering is expected to close on July 9, 2025, subject to customary closing conditions. Alibaba Group Prices Offering of HK$12.023 Billion of Zero Coupon Exchangeable Bonds Share When issued, the Bonds will be unsecured and unsubordinated obligations of Alibaba Group. The Bonds will not bear regular interest. The Bonds will mature on July 9, 2032, unless redeemed, exchanged or purchased in accordance with their terms prior to such date. Holders of the Bonds may exchange all or any portion of the Bonds at their option at any time on or after the 41st day following the issue date of the Bonds to, and including, the close of business on the fifth scheduled trading day immediately preceding the maturity date of the Bonds. Upon exchange, the Company may, at its option, elect to satisfy its exchange obligation by delivering AH Shares, cash, or a combination of cash and AH Shares, each in accordance with the terms set forth in the Bonds. Alibaba Health is a consolidated subsidiary of Alibaba Group, in which Alibaba Group holds approximately 64% of equity interest. Alibaba Group expects Alibaba Health to remain a flagship healthcare platform and consolidated subsidiary of Alibaba Group upon issuance and following any future exchange of the Bonds into AH Shares, and will continue close collaboration with Alibaba Health and members of Alibaba ecosystem to drive 'AI + Healthcare' industry transformation. The initial exchange ratio of the Bonds will be approximately 160,513.6 AH Shares per HK$1,000,000 principal amount of Bonds, which is equivalent to an initial exchange price of HK$6.23 per AH Share. The initial exchange price represents a premium of 48% over the per-share price in the Delta Placement described below, which was HK$4.21 per AH Share. Based on the initial exchange price and assuming the Bonds are exchanged in full for AH Shares, the initial exchange property referenced by the Bonds will represent up to approximately 12% of the issued share capital of Alibaba Health as of May 31, 2025. The exchange price, and accordingly the exchange ratio, will be subject to certain customary adjustments on the terms set forth in the Bonds. In addition, following certain corporate events that occur prior to the fifth scheduled trading day immediately preceding the maturity date or following our delivery of a notice of redemption, we will, in certain circumstances, increase the exchange ratio of the Bonds for a holder who elects to exchange its Bonds in connection with such a corporate event or redemption, as the case may be, as further described below. Holders of the Bonds may require the Company to redeem all or part of their Bonds for cash on July 9, 2030, or following the occurrence of certain corporate events, subject to certain conditions. The redemption price, in each case, will be equal to 100% of the principal amount of the Bonds to be redeemed. The Company may redeem all but not part of the Bonds in the event of certain tax law changes (the 'Tax Redemption'). The Company may also redeem all but not part of the Bonds at any time if less than 10% of the aggregate principal amount of the Bonds originally issued remains outstanding at such time (the 'Cleanup Redemption'). Except in connection with a Tax Redemption or a Cleanup Redemption, the Company may not redeem the Bonds prior to July 9, 2030. At any time after July 9, 2030, the Company may also redeem for cash all or part of the Bonds if the Closing Price (as defined) of AH Shares has been at least 130% of the exchange price then in effect on each of at least 20 trading days (whether or not consecutive) out of 30 consecutive trading days, the last of which occurs not more than five trading days prior to the date the Company provides notice of redemption (such redemption, an 'Optional Redemption'). The redemption price in the case of a Tax Redemption, a Cleanup Redemption or an Optional Redemption will equal to 100% of the principal amount of the Bonds to be redeemed. Alibaba Group estimates that the net proceeds from the Bond Offering will be approximately HK$11.9 billion, after deducting the bookrunners' commissions and estimated offering expenses payable by the Company, which expenses are subject to finalization. Alibaba Group intends to use the net proceeds from the Bond Offering for general corporate purposes, including investments to support the development of our Cloud infrastructure and international commerce businesses. The Bonds are expected to be listed on the Vienna MTF operated by the Vienna Stock Exchange within 60 days after closing of the Bond Offering. Investor Hedging Transactions The Company expects that certain purchasers of the Bonds may employ a convertible arbitrage strategy by short selling AH Shares or by entering into short derivative positions with respect to AH Shares to hedge their exposure to the Bonds. Any such activity could take place concurrently with or shortly after the pricing of the Bonds and could lead to any decline (or offset against any appreciation) of the market price of AH Shares or any securities referencing AH Shares, including the Bonds. Further, such investors may dynamically modify their hedges from time to time while the Bonds are outstanding, by short selling or purchasing AH Shares in secondary market transactions or entering into equivalent derivative positions, which could affect the market price of AH Shares or any securities referencing AH Shares at the time, including the Bonds. Concurrently with the pricing of the Bonds, certain bookrunners of the Bond Offering facilitated a sale of AH Shares, representing the expected initial delta of such hedging investors' short position, in privately negotiated transactions solely to non-U.S. persons outside of the United States (such sale, a 'Delta Placement'). In connection with the Delta Placement, a wholly-owned subsidiary of the Company (the 'Lender') has entered into a stock borrowing and lending arrangement with an affiliate of one of the bookrunners (the 'Borrower'), pursuant to which the Lender has committed to lending a certain number of AH Shares (the 'Borrowed Shares') to the Borrower. The Borrower has agreed to on-lend a portion of the Borrowed Shares to the other bookrunners to facilitate hedging activities of certain investors in the Bonds. Other Matters The Bonds, the AH Shares deliverable upon exchange of the Bonds, if any, and the Borrowed Shares (collectively, the 'Securities'), have not been and will not be registered under the Securities Act or any U.S. state securities laws, and are being offered and sold to certain non-U.S. persons in offshore transactions outside the United States in reliance on Regulation S under the Securities Act. The Securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act. This press release shall not constitute an offer to sell or a solicitation of an offer to purchase any securities, in the United States or elsewhere, and shall not constitute an offer, solicitation or sale of the securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful. This press release contains information about the pending Bond Offering and Delta Placement of Borrowed Shares, and there can be no assurance that the Bond Offering and/or the Delta Placement of Borrowed Shares will be completed. All translations of U.S. dollars, Renminbi and Euros into Hong Kong dollars in this press release were made at a rate of US$1.00 to HK$7.8499, RMB1.00 to HK$1.0960 and €1.00 to HK$9.2593, respectively. About Alibaba Group Alibaba Group's mission is to make it easy to do business anywhere. The Company aims to build the future infrastructure of commerce. It does not pursue size or power. It aspires to be a company that will last for 102 years. Safe Harbor Statement This press release contains forward-looking statements. These statements are made under the 'safe harbor' provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as 'may,' 'will,' 'expect,' 'anticipate,' 'future,' 'aim,' 'estimate,' 'intend,' 'seek,' 'plan,' 'believe,' 'potential,' 'continue,' 'ongoing,' 'target,' 'guidance,' 'is/are likely to' and similar statements. In addition, statements that are not historical facts, including statements about the intended use of proceeds, the terms of the Bonds, the Delta Placement and stock lending arrangement, future relationship between Alibaba Group and Alibaba Health, whether the Company will complete the Bond Offering, and the expected listing of the Bonds, are or contain forward-looking statements. Alibaba may also make forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the 'SEC'), in announcements made on the website of the Hong Kong Stock Exchange, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement. Further information regarding these risks is included in Alibaba's filings with the SEC and announcements on the website of the Hong Kong Stock Exchange. All information provided in this press release is as of the date of this press release and are based on assumptions that we believe to be reasonable as of this date, and Alibaba does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
Yahoo
a day ago
- Yahoo
Is Hims & Hers Stock in Trouble?
Hims & Hers Health and Novo Nordisk announced a partnership a few months ago, and it has already come to an end. Novo Nordisk is concerned about the telehealth company's practices, particularly relating to compounded drugs. 10 stocks we like better than Hims & Hers Health › Hims & Hers Health (NYSE: HIMS) is a telehealth company that offers personalized solutions for its customers. And demand has been robust, with subscriptions for its products rising significantly in recent years. While telehealth has for the most part not been a hot place to invest in, Hims & Hers Health has been the exception to that. Last year, its share price jumped by 172%. And this year, shares have already more than doubled in value (returns as of June 27). Recently, however, its share price took a hit amid some troubling news involving Novo Nordisk (NYSE: NVO), the healthcare company behind popular diabetes and weight loss drugs Ozempic and Wegovy. And it raised questions about Hims & Hers' business practices. Here's what you need to know about these recent developments and whether you should be thinking twice about buying Hims & Hers stock. In April, the two companies announced they would collaborate to make it easier for Americans to gain access to effective obesity treatments. Through the Hims & Hers platform, people would be able to obtain Wegovy for $599 per month. And it seemed as if it would be the start of a promising long-term partnership. Hims & Hers CEO Andrew Dudum said, "We share a vision of what consumer-centered healthcare looks like, and this is just the first step toward delivering that future." It sounded like a great way for Hims & Hers Health to bring popular drugs onto its platform. And for Novo Nordisk, it would be an opportune way to reach more customers. Less than two months later, the partnership is over. Novo Nordisk expressed concerns over Hims & Hers marketing practices, which it referred to as "deceptive" and that it "failed to adhere to the law which prohibits mass sales of compounded drugs." Hims & Hers specializes in selling compounded drugs, which are copies of FDA-approved drugs using adjusted (and unapproved) formulas. They are often made by foreign suppliers and occasionally contain active ingredients that may not be safe. Compounding is used for various appropriate reasons (like certain patients needing a modified version to account for a specific issue) as well as when a drug is in short supply. Among drugmakers, it is considered a controversial practice. Both Wegovy and Ozempic were OK'd for compounding for a time to deal with supply shortages, but that is no longer an issue. Hims & Hers is justifying the continued use of compounded drugs because it says it offers personalized compounded versions that it says are medically necessary. Novo Nordisk doesn't agree with this practice. Novo Nordisk may have expected that with the partnership, Hims & Hers wouldn't offer compounded versions of its drugs anymore and would instead simply offer the real drugs. Hims & Hers has been a growth beast over the years. It went from just $272 million in revenue in 2021 to $1.8 billion in sales over the trailing 12 months. It has also gone from being in the red financially to now generating significant profits; earnings over the past four quarters have totaled $164 million -- more than 9% of its top line. The business has evolved by offering a wider range of products to its customers, including obesity treatments. But in doing so, it has been pushing the envelope with compounded drugs, and the danger is that patients could experience side effects and consequences that may otherwise not happen with FDA-approved drugs. My concern is that the business could open itself up to potential legal issues down the road. It is winning over customers by offering low-cost, personalized solutions, but the way it's going about that could lead to significant risk in the future. Plus, if the company ends up having to stop selling compounded drugs, that could thwart its growth prospects. Hims & Hers has done incredibly well in recent years. But with question marks about its future growth, the potential legal risk ahead, and a high valuation (it trades at more than 70 times its trailing earnings), this isn't a stock I would rush to buy right now. Before you buy stock in Hims & Hers Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Hims & Hers Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $722,181!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $968,402!* Now, it's worth noting Stock Advisor's total average return is 1,069% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 30, 2025 David Jagielski has positions in Novo Nordisk. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Is Hims & Hers Stock in Trouble? was originally published by The Motley Fool
Yahoo
a day ago
- Yahoo
Craig-Hallum Initiates Coverage of Butterfly (BFLY) With a Buy Rating
Butterfly Network, Inc. (NYSE:BFLY) is one of the top 10 healthcare AI stocks to buy according to hedge funds. Craig-Hallum analyst Chase Knickerbocker has initiated coverage of Butterfly Network, Inc. (NYSE:BFLY) with a Buy rating and a $3 price target, citing the company's disruptive position in the point-of-care ultrasound market. Butterfly's proprietary technology replaces traditional piezoelectric crystal-based ultrasound components with a chip-based semiconductor platform, allowing for a single probe to handle multiple imaging needs. This innovation not only reduces manufacturing complexity and cost, but also enables rapid software-driven improvements that set Butterfly apart from most handheld competitors. A doctor looking at a ultrasound system with a Compass software interface, demonstrating the sophistication of the device. The firm's outlook is underpinned by Butterfly's expanding direct-to-consumer (DTC) reach and a growing number of institutional partnerships, including leading health systems and academic centers. These relationships are expected to drive consistent hardware sales while building recurring revenue from software subscriptions. Butterfly Network's technology also places it at the forefront of healthcare's digital transformation. By combining advanced imaging with real-time data interpretation and cloud-based collaboration tools, the company is integrating AI into clinical workflows to enhance diagnostic speed and accuracy. While we acknowledge the potential of BFLY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BFLY and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Best Biotech Stocks To Invest In Now and 12 Best Healthcare Stocks to Buy Now. Disclosure: None. Sign in to access your portfolio
